SNFGE SNFGE
 
Thématique :
- Foie
Originalité :
Réexamen
Solidité :
A confirmer
Doit faire évoluer notre pratique :
Dans certains cas
 
 
Nom du veilleur :
Professeur Christine SILVAIN
Coup de coeur :
 
 
Hepatology
  2016/11  
 
  2016 Nov;64(5):1507-1517  
  10.1002/hep.28778  
 
  Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B.  
 
  Cheng JY, Wong VW, Tse YK, Chim AM, Chan HL, Wong GL  
  https://www.ncbi.nlm.nih.gov/pubmed/27680510  
 
 

Abstract

Metabolic syndrome is an independent risk factor of liver cirrhosis in chronic hepatitis B (CHB). Whether metabolic syndrome affects the long-term prognosis of CHB patients in terms of hepatic events, cardiovascular events, and death remains unknown. We aimed to determine the incidences of hepatic events, cardiovascular events, and death in CHB patients with or without metabolic syndrome. From 2006 to 2008, we prospectively recruited 1,466 CHB patients for liver stiffness measurement (LSM) with transient elastography together with detailed metabolic profiling as baseline assessment. Patients were prospectively followed for any clinical events. The impact of LSM and metabolic syndrome on hepatic events, cardiovascular events, and death was evaluated. At baseline visit, the mean age was 46 ± 12 years, LSM value was 8.4 ± 6.3 kPa, and 188 patients (12.8%) had metabolic syndrome. At a mean follow-up of 88 ± 20 months, 93 and 44 patients developed hepatic and cardiovascular events, respectively; 70 patients died. Patients with baseline LSM >8.0 kPa had higher cumulative probability of hepatic events than those with LSM ≤8.0kPa at 8 years (12.3% versus 3.1%, P < 0.001). Patients with metabolic syndrome had higher cumulative probability of cardiovascular events than those without (8.0% versus 2.1%, P < 0.001). High LSM had no impact on cardiovascular events; neither did metabolic syndrome on hepatic events. LSM >8.0 kPa but not metabolic syndrome was an independent risk factor of death, with adjusted hazard ratios of 1.9 (95% confidence interval 1.1-3.2, P = 0.023) and 1.3 (95% confidence interval 0.8-2.4, P = 0.310), respectively.

CONCLUSIONS:

Metabolic syndrome increased the risk of cardiovascular events but not hepatic events and death; LSM was the important risk factor of hepatic events and death in CHB patients. (Hepatology 2016;64:1507-1517).

 
Question posée
 
Quelle est l’incidence des complications hépatiques et cardio-vasculaire et des décès chez les patients ayant une hépatite chronique virale B associée ou non à un syndrome métabolique ?
 
Question posée
 
Les patients ayant à baseline une élasticité >8.0 kPa ont un risque plus important de complications hépatiques et ceux ayant un syndrome métabolique ont plus de risque de développer des complications cardio-vasculaires. L’élasticité >8.0 kPa et non le syndrome métabolique est un facteur indépendant de décès.
 
Commentaires

La recherche d’un syndrome métabolique et de ses risques cardiovasculaires est aussi nécessaire chez les patients ayant une hépatite B ce d’autant que la fibrose hépatique est significative.  Ce n’est pas forcément un scoop …

 
www.snfge.org